Cargando…
The Relationship of Hematological Parameters and C-reactive Protein (CRP) With Disease Presence, Severity, and Response to Systemic Therapy in Patients With Psoriasis
Objectives: Systemic inflammation has an important role in psoriasis, which is a chronic disease with an increasing prevalence and is associated with comorbidity. Our aim is to investigate the relationship of hematological parameters and C-reactive protein (CRP) with the presence and severity of the...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507996/ https://www.ncbi.nlm.nih.gov/pubmed/37731441 http://dx.doi.org/10.7759/cureus.43790 |
_version_ | 1785107435243962368 |
---|---|
author | Şener, Gülsen İnan Yuksel, Esma Gökdeniz, Osman Karaman, Kübra Canat, Harbiye Dilek |
author_facet | Şener, Gülsen İnan Yuksel, Esma Gökdeniz, Osman Karaman, Kübra Canat, Harbiye Dilek |
author_sort | Şener, Gülsen |
collection | PubMed |
description | Objectives: Systemic inflammation has an important role in psoriasis, which is a chronic disease with an increasing prevalence and is associated with comorbidity. Our aim is to investigate the relationship of hematological parameters and C-reactive protein (CRP) with the presence and severity of the disease in patients with psoriasis. It is also to investigate whether it can be used as a biomarker in monitoring the response to systemic treatment. Materials and methods: This retrospective study was conducted with the participation of 139 psoriasis patients receiving biological therapy (BT) and conventional therapy (CT) and 140 healthy controls. Demographic, clinical, and laboratory data of patients and controls were examined and all parameters were compared with the psoriasis area severity index (PASI) score. In addition, the changes in these parameters before the treatment and in the third month of the treatment were examined in the patient groups who received BT and CT. Results: White blood cell (WBC), neutrophil, monocytes, platelet (PLT), plateletcrit, red blood cell, neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR) monocyte-lymphocyte ratio (MLR), red cell distribution width (RDW), CRP and erythrocytesedimentation (ESR) levels were higher compared to the healthy control group in psoriasis patients (p<0.05). Baseline PASI values were positively correlated with WBC, neutrophils, monocytes, NLR, MLR, and CRP. WBC, neutrophil, NLR, CRP, and ESR levels decreased in all patients in the third month of treatment (p<0.05). WBC, PLT, neutrophil, and NLR in patients receiving BT; while WBC, neutrophil, NLR, CRP, and ESR levels decreased in patients receiving CT, RDW levels increased (p<0.05). Adalimumab; NLR and basophil, methotrexate; WBC, NLR, neutrophil, and ESR levels caused a significant decrease (p<0.05). Conclusion: The fact that increased WBC, neutrophils, monocytes, NLR, MLR, and CRP levels are associated with the severity of psoriasis indicates that these parameters reflect systemic inflammation in psoriasis. In addition, the decrease in these parameters after BT and CT suggests that they can be considered simple and reliable markers that can be used as a complement to the PASI score in assessing disease severity and response to treatment. |
format | Online Article Text |
id | pubmed-10507996 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-105079962023-09-20 The Relationship of Hematological Parameters and C-reactive Protein (CRP) With Disease Presence, Severity, and Response to Systemic Therapy in Patients With Psoriasis Şener, Gülsen İnan Yuksel, Esma Gökdeniz, Osman Karaman, Kübra Canat, Harbiye Dilek Cureus Dermatology Objectives: Systemic inflammation has an important role in psoriasis, which is a chronic disease with an increasing prevalence and is associated with comorbidity. Our aim is to investigate the relationship of hematological parameters and C-reactive protein (CRP) with the presence and severity of the disease in patients with psoriasis. It is also to investigate whether it can be used as a biomarker in monitoring the response to systemic treatment. Materials and methods: This retrospective study was conducted with the participation of 139 psoriasis patients receiving biological therapy (BT) and conventional therapy (CT) and 140 healthy controls. Demographic, clinical, and laboratory data of patients and controls were examined and all parameters were compared with the psoriasis area severity index (PASI) score. In addition, the changes in these parameters before the treatment and in the third month of the treatment were examined in the patient groups who received BT and CT. Results: White blood cell (WBC), neutrophil, monocytes, platelet (PLT), plateletcrit, red blood cell, neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR) monocyte-lymphocyte ratio (MLR), red cell distribution width (RDW), CRP and erythrocytesedimentation (ESR) levels were higher compared to the healthy control group in psoriasis patients (p<0.05). Baseline PASI values were positively correlated with WBC, neutrophils, monocytes, NLR, MLR, and CRP. WBC, neutrophil, NLR, CRP, and ESR levels decreased in all patients in the third month of treatment (p<0.05). WBC, PLT, neutrophil, and NLR in patients receiving BT; while WBC, neutrophil, NLR, CRP, and ESR levels decreased in patients receiving CT, RDW levels increased (p<0.05). Adalimumab; NLR and basophil, methotrexate; WBC, NLR, neutrophil, and ESR levels caused a significant decrease (p<0.05). Conclusion: The fact that increased WBC, neutrophils, monocytes, NLR, MLR, and CRP levels are associated with the severity of psoriasis indicates that these parameters reflect systemic inflammation in psoriasis. In addition, the decrease in these parameters after BT and CT suggests that they can be considered simple and reliable markers that can be used as a complement to the PASI score in assessing disease severity and response to treatment. Cureus 2023-08-20 /pmc/articles/PMC10507996/ /pubmed/37731441 http://dx.doi.org/10.7759/cureus.43790 Text en Copyright © 2023, Şener et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Dermatology Şener, Gülsen İnan Yuksel, Esma Gökdeniz, Osman Karaman, Kübra Canat, Harbiye Dilek The Relationship of Hematological Parameters and C-reactive Protein (CRP) With Disease Presence, Severity, and Response to Systemic Therapy in Patients With Psoriasis |
title | The Relationship of Hematological Parameters and C-reactive Protein (CRP) With Disease Presence, Severity, and Response to Systemic Therapy in Patients With Psoriasis |
title_full | The Relationship of Hematological Parameters and C-reactive Protein (CRP) With Disease Presence, Severity, and Response to Systemic Therapy in Patients With Psoriasis |
title_fullStr | The Relationship of Hematological Parameters and C-reactive Protein (CRP) With Disease Presence, Severity, and Response to Systemic Therapy in Patients With Psoriasis |
title_full_unstemmed | The Relationship of Hematological Parameters and C-reactive Protein (CRP) With Disease Presence, Severity, and Response to Systemic Therapy in Patients With Psoriasis |
title_short | The Relationship of Hematological Parameters and C-reactive Protein (CRP) With Disease Presence, Severity, and Response to Systemic Therapy in Patients With Psoriasis |
title_sort | relationship of hematological parameters and c-reactive protein (crp) with disease presence, severity, and response to systemic therapy in patients with psoriasis |
topic | Dermatology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507996/ https://www.ncbi.nlm.nih.gov/pubmed/37731441 http://dx.doi.org/10.7759/cureus.43790 |
work_keys_str_mv | AT senergulsen therelationshipofhematologicalparametersandcreactiveproteincrpwithdiseasepresenceseverityandresponsetosystemictherapyinpatientswithpsoriasis AT inanyukselesma therelationshipofhematologicalparametersandcreactiveproteincrpwithdiseasepresenceseverityandresponsetosystemictherapyinpatientswithpsoriasis AT gokdenizosman therelationshipofhematologicalparametersandcreactiveproteincrpwithdiseasepresenceseverityandresponsetosystemictherapyinpatientswithpsoriasis AT karamankubra therelationshipofhematologicalparametersandcreactiveproteincrpwithdiseasepresenceseverityandresponsetosystemictherapyinpatientswithpsoriasis AT canatharbiyedilek therelationshipofhematologicalparametersandcreactiveproteincrpwithdiseasepresenceseverityandresponsetosystemictherapyinpatientswithpsoriasis AT senergulsen relationshipofhematologicalparametersandcreactiveproteincrpwithdiseasepresenceseverityandresponsetosystemictherapyinpatientswithpsoriasis AT inanyukselesma relationshipofhematologicalparametersandcreactiveproteincrpwithdiseasepresenceseverityandresponsetosystemictherapyinpatientswithpsoriasis AT gokdenizosman relationshipofhematologicalparametersandcreactiveproteincrpwithdiseasepresenceseverityandresponsetosystemictherapyinpatientswithpsoriasis AT karamankubra relationshipofhematologicalparametersandcreactiveproteincrpwithdiseasepresenceseverityandresponsetosystemictherapyinpatientswithpsoriasis AT canatharbiyedilek relationshipofhematologicalparametersandcreactiveproteincrpwithdiseasepresenceseverityandresponsetosystemictherapyinpatientswithpsoriasis |